The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of an abbreviated new drug application (ANDA) for methylphenidate hydrochloride (HCl) extended-release (ER) tablets and is announcing an opportunity for the holder of the ANDA to request a hearing on this proposal.
Document
Mallinckrodt Pharmaceuticals; Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets; Opportunity for a Hearing
The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of an abbreviated new drug application (ANDA)...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 71737
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Mallinckrodt Pharmaceuticals; Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets; Opportunity for a Hearing,” thefederalregister.org (October 18, 2016), https://thefederalregister.org/documents/2016-25093/mallinckrodt-pharmaceuticals-proposal-to-withdraw-approval-of-an-abbreviated-new-drug-application-for-extended-release-m.